CAR T Referral Process: Insights From Kansas : Episode 6

Approaches to Bridging Therapy During the CAR T Manufacturing Process

January 24, 2025

By Al-Ola Abdallah, MD
Muhammad Umair Mushtaq, MD

Opinion

Video

Panelists discuss how bridging therapy during the CAR T manufacturing waiting period requires careful patient-specific decisions about whether to use chemotherapy, targeted agents, or observation alone, based on disease aggressiveness, patient condition, and expected manufacturing timeframes.

EP: 1.Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM

EP: 2.Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?

EP: 3.Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria

EP: 4.University of Kansas Medical Center Insights: CAR T Referral Process

EP: 5.Reviewing CAR T Mechanism & Treatment Process

Now Viewing

EP: 6.Approaches to Bridging Therapy During the CAR T Manufacturing Process

EP: 7.Comanaging Cases of RR/MM in Patients Receiving CAR T

EP: 8.On-going Clinical Trials With CAR T Therapy in Earlier-Line Multiple Myeloma Treatment: Future Perspectives

EP: 9.Expert Insights: 68yM High-Risk R/R MM Post HSCT With Progressive Disease—Next Steps?

EP: 10.Expert Insights: Key Takeaways & Clinical Pearls on CAR T Therapy in R/R MM

Video content above is prompted by the following:

Can you explain your institution’s approach to bridging therapy for patients awaiting CAR T-cell manufacturing and infusion?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!